Back to User profile » Dr Xiaomin Yang
Paper published by Dr Xiaomin Yang:
Original Research
Tivozanib versus Sorafenib as Subsequent-Line Therapy for Advanced Renal Cell Carcinoma: A Cost-Effectiveness Analysis from a US Healthcare Perspective
Zhang X, Liu R, Hu Y, Ye J, Yang M, Xu J, Yang H, Yang X, Xu Z, Dai H, Xu H
Risk Management and Healthcare Policy 2026, 19:617441
Published Date: 23 July 2026